Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Locoregional treatment of low-grade B-cell lymphoma with CD3xCD19 bispecific antibodies and CD28 costimulation. II. Assessment of cellular immune responses.

International journal of cancer - 15 Feb 2001

Manzke O, Tesch H, Lorenzen J, Diehl V, Bohlen H

Abstract excerpt

Ten patients with advanced B-cell lymphoma were treated with a single locoregional injection of CD3xCD19 bispecific and costimulating CD28 monospecific antibodies to activate tumor-infiltrating T-lymphocytes. Antibodies were administered at 4 different dose levels (30 microg, 270 microg, 810 microg, 1,600 microg of each antibody) either by intratumoral or intralymphatic injection. Most patients developed...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Bispecific
Share to Antigens, CD19

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to CD28 Antigens

Share to CD3 Complex

Share to In Situ Nick-End Labeling

Share to Leukemia, B-Cell

Share to Lymphoma, Follicular

Share to Lymphoma, Mantle-Cell

Source

Identifiers

PMID: 11251975
DOI: 10.1002/1097-0215(200002)9999:9999<::aid-ijc1069>3.0.co;2-a

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 8 closest

Locoregional treatment of low-grade B-cell lymphoma with CD3xCD19 bispecific antibodies and CD28 costimulation. II. Assessment of cellular immune responses.PMID 11251975Read ↗

Locoregional alpha-radioimmunotherapy of intraperitoneal tumor cell dissemination using a tumor-specific monoclonal antibody.Semantic proximity Read ↗

Endolymphatic delivery of IL2 in patients with melanoma and lymphoma.Semantic proximity Read ↗

DuoBody-CD3xCD20 induces potent T-cell-mediated killing of malignant B cells in preclinical models and provides opportunities for subcutaneous dosing.Semantic proximity Read ↗

GPR183 mediates the capacity of the novel CD47-CD19 bispecific antibody TG-1801 to heighten ublituximab-umbralisib (U2) anti-lymphoma activitySemantic proximity Read ↗

Principles and Current Clinical Landscape of Multispecific Antibodies against CancerSemantic proximity Read ↗

Future perspectives on novel CAR-T therapeutics beyond CD19 and BCMA in onco-hematologySemantic proximity Read ↗

T-cell engager bispecific antibodies enable T cells to eliminate Multiple Myeloma by targeting tumor CD38 in combination with PD-L1Semantic proximity Read ↗

CEA-4-1BBL: Design and Optimization of a Novel CEACAM5-Targeted 4-1BB Ligand Antibody Fusion Protein to Provide Costimulation in Cis in Combination with T Cell Bispecific AntibodiesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.